Posted by Michael Wonder on 29 Jun 2023
Ontario to publicly reimburse Albrioza for the treatment of ALS
28 June 2023 - Ontario lists Albrioza on its drug benefit formulary, becoming the first province to publicly reimburse Albrioza, effective 22 June 2023,
Amylyx Pharmaceuticals Canada announced today that the Company has entered into a Product Listing Agreement with Ontario for the public reimbursement of Albrioza (sodium phenylbutyrate and ursodoxicoltaurine) through the Ontario Drug Benefit Program effective 22 June 2023.
